Menu Search
Equities

Glycorex Transplantation AB (publ)

O33:FRA

Glycorex Transplantation AB (publ)

Actions
  • Price (EUR)0.1085
  • Today's Change0.009 / 9.15%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 08:38 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Glycorex Transplantation AB (publ)'s revenues fell -17.04% from 36.12m to 29.96m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 8.58m to a larger loss of 30.36m.
Gross margin82.91%
Net profit margin-89.70%
Operating margin-88.71%
Return on assets-36.96%
Return on equity-53.31%
Return on investment-46.32%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at Glycorex Transplantation AB (publ) fell by 19.74m. Cash Flow from Investing was negative at 3.55m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 9.46m for operations while cash used for financing totalled 6.63m.
Cash flow per share-0.085
Price/Cash flow per share--
Book value per share0.5186
Tangible book value per share0.2361
More ▼

Balance sheet in SEKView more

Glycorex Transplantation AB (publ) has a Debt to Total Capital ratio of 20.84%, a higher figure than the previous year's 14.92%.
Current ratio1.51
Quick ratio1.09
Total debt/total equity0.2633
Total debt/total capital0.2084
More ▼

Growth rates in SEK

SmartText is unavailable
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-152.29
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.